Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05949593 · ClinicalTrials.gov registry record · Phase 3
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
A Phase 3 study of Geographic Atrophy, sponsored by Belite Bio.
- Active
- Registry status
- Phase 3
- Development phase
- 429
- Enrollment target
- 20
- Study locations
NCT05949593: Active Phase 3 study of Geographic Atrophy, sponsored by Belite Bio.
NCT05949593 is a Phase 3 study of Geographic Atrophy that is active but no longer recruiting, run by Belite Bio. The registered enrollment target is 429 participants, above the 206-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (108% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05949593, a Phase 3 study of Geographic Atrophy, is active but no longer recruiting, sponsored by Belite Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 429 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tinlarebant
Study Locations (20)
California
- Belite Study Site - Arcadia
- Belite Study Site - Beverly Hills
- Belite Study Site - Huntington Beach
- Belite Study Site - Los Angeles
- Belite Study Site - Palo Alto
- Belite Study Site - San Diego
North Carolina
- Belite Study Site - Cary
- Belite Study Site - Durham
- Belite Study Site - Wake Forest
Pennsylvania
- Belite Study Site - Philadelphia
- Belite Study Site - Sewickley
Texas
- Belite Study Site - Abilene
- Belite Study Site - Dallas
Arizona
- Belite Study Site - Phoenix
Florida
- Belite Study Site - Lakeland
Maryland
- Belite Study Site - Hagerstown
Minnesota
- Belite Study Site - Saint Louis Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 429 participants |
| Start Date | 2023-07-27 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 3 |
What the registry record for NCT05949593 still lists
NCT05949593 is an interventional study that assigns participants to a tested intervention. The registered 429 participants enrollment target is mid-sized for trials with a published cap, above the 206-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (108% higher).
The record links to 1 condition, with Geographic Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05949593 names 20 study sites across 11 states, led by California, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05949593 about?
NCT05949593 is a clinical study titled "Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy". This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
What is the current status of trial NCT05949593?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 429 participants. The study started on 2023-07-27. Estimated completion is 2027-08-31.
What conditions does trial NCT05949593 study?
This clinical trial studies the following conditions: Geographic Atrophy.
What interventions are being tested in trial NCT05949593?
The interventions under investigation include: Placebo (DRUG), Tinlarebant (DRUG).
Who is sponsoring clinical trial NCT05949593?
This trial is sponsored by Belite Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05949593 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05949593's enrollment target sits among peer trials
429 5th of 27 higher than 23 of 27 other Geographic Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Geographic Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
COMPLETED · Phase 3
-
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05932862 · 429 participants · Phase 1
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI